RxDoctor Payments Data

Jason Crowl, NP

Family · Bel Air, MDNPI 1518520923

Payments from drug & device makers

$2,661in general payments, 2019–2025

Across 122 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$528
  • AstraZeneca$509
  • Astellas Pharma US Inc$411
  • Pfizer$315
  • Lilly USA, LLC$190
  • Amgen$117
  • plus $591 from 16 others

What the payments were for

  • Food & beverage$2,49794%
  • Education$1646%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,661 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$13,647
Medicare patients
74
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$41,976
Rosuvastatin Calcium47$643
Levothyroxine Sodium34$337
Albuterol Sulfate HfaAlbuterol Sulfate11$329
Cefdinir18$320
Fluoxetine Hcl13$298
Atorvastatin Calcium31$289
Metoprolol Succinate17$232
Pantoprazole Sodium31$200
Amlodipine Besylate37$182
Metformin Hcl24$162
Allopurinol13$122
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$118
Prednisone42$118
Doxycycline Hyclate18$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$528$41,97638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.

Other family in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →